Ethics approval and consent to participate
The study protocol was approved by the ethics committee of HM Hospitales (Code: 20.05.1633-GHM) and performed according to the Declaration of Helsinki and local laws and regulations. Patients provided written informed consent. Informed consent was not required from inaccessible patients according to Spanish laws.
Consent to publish
Not applicable.
Conflict of interest
AY: Consulting or advisory role: Clovis Oncology, GSK, AstraZeneca, MSD, PharmaMar, Roche. Travel, accommodation, expenses: MSD, GSK, PharmaMar.
AB: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PE: Consulting fees and honoraria for lectures, presentations, speaker bureaus: MSD, GSK, AstraZeneca, Clovis Oncology and PharmaMar.
BP: Consulting or advisory role: Clovis Oncology, Novartis, AstraZeneca. Travel, accommodation: AstraZeneca.
LS: Consulting or advisory role: GSK-Tesaro, Clovis Oncology, AstraZeneca, MSD, Roche. Travel, accommodation, expenses: GSK, MSD, PharmaMar.
PR: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
JA: Consulting or advisory role: GSK, Clovis, AstraZeneca, MSD, Roche. Travel, accommodation, expenses: GSK, MSD, PharmaMar.
JC: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
LG: Consulting fees and honoraria for lectures, presentations, speaker bureaus: MSD, GSK, AstraZeneca, Clovis Oncology and PharmaMar.
JF: Advisory Board: Roche, AstraZeneca, Clovis Oncology and GSK.
AS: Consulting fees and honoraria for lectures, presentations, speaker bureaus: MSD, GSK, AstraZeneca, Clovis Oncology, Pfizer, Lilly, Novartis.
CS: Consulting or advisory role: PharmaMar. Travel, accommodation, expenses: GSK, MSD, Pfizer, AstraZeneca.
LM: Consulting or advisory role: Roche/Genentech, AstraZeneca, Novartis, Pfizer, Tesaro, Eisai, Lilly, Clovis Oncology, Pierre Fabre, GlaxoSmithKline. Speakers’ Bureau: Roche/Genentech, Novartis, Pfizer, AstraZeneca, Lilly. Research Funding: Tesaro.
AH: Principal investigator of clinical trials: AstraZeneca, Roche. Member of advisory boards: GSK. Personal fees: Clovis Oncology, GSK, MSD and PharmaMar.
AT: Personal fees and non-financial support: Roche, BMS, MSD, GSK, AstraZeneca and Pfizer.
RM: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
JM: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
MM: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
GM: Consulting fees and honoraria for lectures, presentations, speaker bureaus: Roche, PharmaMar, GSK/Tesaro, MSD, AstraZeneca, Clovis Oncology, Medicamenta, Lilly, Pfizer.
VC: Consulting or advisory role: GSK, AstraZeneca, MSD, PharmaMar. Travel, accommodation, expenses: GSK, AstraZeneca, MSD, PharmaMar.
MC: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
MG: The author declares no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
AD: Employee and owner of stock and stock options in Clovis Oncology, Inc.
AGM: Advisory/Consultancy: Alkermes, Amgen, AstraZeneca, Clovis Oncology, Genmab, GSK, ImmunoGen, Merck Sharp & Dohme, macrogenmics, Novartis, Oncoinvent, Pfizer/Merck, PharmaMar, Roche, Sotio, Sutro. Speaker Bureau: AstraZeneca, PharmaMar, Roche, GSK, Clovis Oncology. Research Grant/Funding: Roche, TESARO: A GSK Company. Travel/Accommodation/Expenses: AstraZeneca, PharmaMar, Roche, TESARO: A GSK Company.